Biote CORP. (BTMD) — SEC Filings

Q: What are the key financial highlights for Biote CORP.?

Key financial highlights for Biote CORP. are extracted from the most recent 10-K or 10-Q filings, including revenue, net income, EPS, debt-to-equity, cash position, and operating margin.

Q: Who are the key executives at Biote CORP.?

Key executives at Biote CORP. are identified from SEC filings including 10-K annual reports, proxy statements, and insider trade forms.

Q: What are the main risk factors for Biote CORP. stock?

Risk factors for Biote CORP. (BTMD) are assessed from SEC filings using AI analysis. Each filing is categorized as high, medium, or low risk based on disclosed risk factors and financial indicators.

Q: What are recent predictions and forward guidance from Biote CORP.?

Forward-looking statements and predictions from Biote CORP. are extracted from SEC filings including earnings reports, annual reports, and current event filings.

Latest SEC filings for Biote CORP.. Recent 4 filing on Apr 3, 2026. AI-decoded analysis of earnings, risk factors, and insider trades.

View Biote CORP. on SEC EDGAR

Overview

Biote CORP. (BTMD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 7, 2025: biote Corp. reported a net income of $9.216 million for the three months ended September 30, 2025, a decrease from $12.657 million in the same period of 2024. For the nine months ended September 30, 2025, net income was $28.980 million, a significant improvement from a net loss of $3.437 million in

Sentiment Summary

Across 42 filings, the sentiment breakdown is: 40 neutral, 2 mixed. The dominant filing sentiment for Biote CORP. is neutral.

Filing Type Overview

Biote CORP. (BTMD) has filed 1 4, 6 10-Q, 24 8-K, 2 DEF 14A, 2 10-K, 5 SC 13G/A, 2 SC 13G with the SEC between Jan 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (42)

4 Filing — 4 · Apr 3, 2026
Biote's Q3 Net Income Dips, But YTD Profitability Soars on Earnout Gains — 10-Q · Nov 7, 2025 Risk: medium
biote Corp. reported a net income of $9.216 million for the three months ended September 30, 2025, a decrease from $12.657 million in the same period of 2024. F
Biote Corp. Files 8-K on Financials — 8-K · Nov 5, 2025 Risk: low
Biote Corp. filed an 8-K on November 5, 2025, reporting on its Results of Operations and Financial Condition, and also including Financial Statements and Exhibi
biote Revenue Jumps 22% Amidst Net Income Dip — 10-Q · Aug 8, 2025 Risk: medium
biote Corp. reported a significant increase in revenue for the three months ended June 30, 2025, reaching $49.7 million, up from $40.8 million in the prior-year
biote Corp. Files 8-K on Financials — 8-K · Aug 6, 2025 Risk: low
biote Corp. filed an 8-K on August 6, 2025, reporting on its Results of Operations and Financial Condition, and Financial Statements and Exhibits. The company,
biote Corp. Announces Director Changes and New Officer Compensation — 8-K · Jun 9, 2025 Risk: medium
On June 5, 2025, biote Corp. filed an 8-K report detailing the departure of Director Dr. David G. Astrella and the appointment of Dr. Jonathan M. Weisberg as a
Biote Corp. Elects New Directors, Reports Executive Compensation — 8-K · Jun 5, 2025 Risk: medium
Biote Corp. announced on June 2, 2025, a change in its board of directors, with the election of two new directors, Dr. David G. Astin and Mr. David L. Schlotter
biote Corp. Files 8-K on Security Holder Vote Matters — 8-K · May 14, 2025 Risk: low
On May 13, 2025, biote Corp. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as Haymaker Acquis
Biote Corp. Q1 2025 10-Q: Earnouts & Equity Plans — 10-Q · May 9, 2025 Risk: medium
Biote Corp. filed its 10-Q for the period ending March 31, 2025, reporting on its financial performance. The filing details various financial instruments and ag
Biote Corp. Files 8-K on Financials and Exit Costs — 8-K · May 7, 2025 Risk: medium
Biote Corp. filed an 8-K on May 7, 2025, reporting on its results of operations and financial condition as of May 1, 2025. The filing also details costs associa
biote Corp. Director Departs, New Director Appointed — 8-K · Apr 24, 2025 Risk: low
On April 22, 2025, biote Corp. announced the departure of Director Jonathan B. Cohen and the appointment of Dr. David L. Katz as a new director. The company als
Biote Corp. Files 2025 Proxy Statement — DEF 14A · Apr 3, 2025 Risk: low
Biote Corp. filed a definitive proxy statement (DEF 14A) on April 3, 2025, for its annual meeting on May 13, 2025. The company, formerly known as Haymaker Acqui
biote Corp. Files 8-K for Reg FD Disclosure — 8-K · Mar 17, 2025 Risk: low
biote Corp. filed an 8-K on March 17, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Haymaker
Biote Corp. Files 2024 10-K, Details Financials — 10-K · Mar 14, 2025 Risk: medium
Biote Corp. filed its 10-K for the fiscal year ending December 31, 2024, reporting on its business as a medicinal chemical and botanical products company. The c
Biote Corp. Files 8-K on Financials — 8-K · Mar 12, 2025 Risk: low
Biote Corp. filed an 8-K on March 12, 2025, reporting on its results of operations and financial condition. The filing also includes financial statements and ex
Biote Corp. Files 8-K on Officer Changes and Financials — 8-K · Jan 30, 2025 Risk: medium
Biote Corp. filed an 8-K on January 30, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain officer
biote Corp. Files 8-K on Financials — 8-K · Nov 12, 2024 Risk: low
biote Corp. filed an 8-K on November 12, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhi
Biote Corp. Files Q3 2024 10-Q — 10-Q · Nov 12, 2024 Risk: medium
Biote Corp. filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates. Key financial items inclu
SC 13G/A Filing — SC 13G/A · Nov 12, 2024
SC 13G Filing — SC 13G · Nov 8, 2024
SC 13G Filing — SC 13G · Oct 22, 2024
Biote Corp. Files Q2 2024 10-Q — 10-Q · Aug 9, 2024 Risk: medium
Biote Corp. filed its 10-Q for the period ending June 30, 2024. The filing details financial performance and business operations, including information related
biote Corp. Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
On August 8, 2024, biote Corp. filed an 8-K report detailing its financial results and condition. The company, previously known as Haymaker Acquisition Corp. II
biote Corp. Signs Material Definitive Agreement — 8-K · Jul 5, 2024 Risk: medium
On June 28, 2024, biote Corp. entered into a material definitive agreement. The company, formerly known as Haymaker Acquisition Corp. III, is based in Irving, T
Biote Corp. Elects New Directors, Reports Executive Compensation — 8-K · Jul 3, 2024 Risk: low
Biote Corp. announced on July 2, 2024, a change in its board of directors, with the election of two new directors, Dr. David L. Katz and Ms. Jennifer L. Johnson
biote Corp. Files 8-K for Material Definitive Agreement — 8-K · Jun 21, 2024 Risk: medium
On June 14, 2024, biote Corp. entered into a material definitive agreement. The company, formerly known as Haymaker Acquisition Corp. III, is involved in the me
biote Corp. Files 8-K on Security Holder Vote Matters — 8-K · May 24, 2024 Risk: low
On May 21, 2024, biote Corp. filed an 8-K report detailing a submission of matters to a vote of security holders. The company, formerly known as Haymaker Acquis
biote Corp. Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 10, 2024 Risk: medium
biote Corp. (BTMD) filed a Quarterly Report (10-Q) with the SEC on May 10, 2024. biote Corp. filed a 10-Q report for the period ending March 31, 2024. The filin
Biote Corp. Files 8-K on Financials — 8-K · May 7, 2024 Risk: low
Biote Corp. filed an 8-K on May 7, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and exhib
biote Corp. Files 8-K: Material Definitive Agreement — 8-K · Apr 29, 2024 Risk: medium
On April 23, 2024, biote Corp. entered into a Material Definitive Agreement. The company, formerly known as Haymaker Acquisition Corp. III, is based in Irving,
biote Corp. Announces 2024 Annual Meeting of Stockholders on May 21 — DEF 14A · Apr 11, 2024 Risk: low
biote Corp. (BTMD) filed a Proxy Statement (DEF 14A) with the SEC on April 11, 2024. Annual meeting to be held virtually on May 21, 2024, at 10:00 a.m. Central
biote Corp. Files 2023 Annual Report (10-K) — 10-K · Mar 15, 2024 Risk: medium
biote Corp. (BTMD) filed a Annual Report (10-K) with the SEC on March 15, 2024. biote Corp. filed its 2023 10-K report on March 15, 2024. The company was former
Biote Corp. Files 8-K for Disclosure and Exhibits — 8-K · Mar 14, 2024 Risk: low
Biote Corp. filed an 8-K on March 14, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Haymaker
Biote Corp. Files 8-K on Financials — 8-K · Mar 12, 2024 Risk: low
Biote Corp. filed an 8-K on March 12, 2024, reporting on its results of operations and financial condition. The filing also includes financial statements and ex
biote Corp. Files 8-K on Material Definitive Agreement — 8-K · Feb 20, 2024 Risk: medium
biote Corp. entered into a Material Definitive Agreement on February 13, 2024, as reported in their 8-K filing. The filing indicates an event related to Regulat
SC 13G/A Filing — SC 13G/A · Feb 14, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
SC 13G/A Filing — SC 13G/A · Feb 13, 2024
LMR Partners Amends Biote Corp. (BTMD) Stake as of Dec 31, 2023 — SC 13G/A · Feb 12, 2024 Risk: low
LMR Partners LLP, a London-based investment firm, has updated its ownership stake in biote Corp. (NASDAQ: BTMD) as of December 31, 2023. This Schedule 13G/A fil
Biote Corp. Confirms Nasdaq Listing and Corporate Details in 8-K — 8-K · Jan 25, 2024
On January 25, 2024, biote Corp. (BTMD) filed an 8-K to update its registration information, specifically confirming its Class A common stock, par value $0.0001
biote Corp. Files 8-K on Operations & Financial Condition — 8-K · Jan 17, 2024
biote Corp. filed an 8-K on January 17, 2024, to report on its results of operations and financial condition, as well as Regulation FD Disclosure. This filing,
biote Corp. Reports Executive/Director Changes & Compensation on Jan 8 — 8-K · Jan 11, 2024
biote Corp. filed an 8-K on January 11, 2024, reporting an event that occurred on January 8, 2024. This filing indicates changes related to the departure or ele

Risk Profile

Risk Assessment: Of BTMD's 32 recent filings, 0 were flagged as high-risk, 16 as medium-risk, and 16 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Biote CORP.'s most recent 10-Q filing (Nov 7, 2025):

Revenue: $47,956,000
Net Income: $9,216,000
EPS: N/A
Debt-to-Equity: N/A
Cash Position: $28,048,000
Operating Margin: N/A
Total Assets: $111,324,000
Total Debt: $103,380,000

Key Executives

Dr. Gary S. Donovitz
Teresa S. Weber
Dr. David G. Astrella
Dr. Jonathan M. Weisberg
Dr. Paul R. Savage
Dr. David G. Astin
Mr. David L. Schlotterbeck
Jonathan B. Cohen
Dr. David L. Katz
Ms. Jennifer L. Johnson
Steven J. Heyer
S. Mark Cone
Debra L. Morris
BEN LEVINE
STEFAN RENOLD

Industry Context

Biote Corp. operates in the biopharmaceutical and life sciences sector, focusing on hormone therapy and related services. The industry is characterized by significant R&D investment, regulatory oversight (FDA), and competitive pressures from both established players and emerging biotech firms. Trends include personalized medicine, advancements in drug delivery, and increasing demand for specialized treatments.

Top Tags

financial-reporting (7) · financials (7) · corporate-governance (5) · 10-Q (4) · company-update (3) · SEC Filing (3) · board-changes (3) · executive-compensation (3) · 8-K (3) · material-definitive-agreement (3)

Key Numbers

Net Income (Q3 2025): $9.216M — Decreased from $12.657M in Q3 2024
Net Income (YTD 2025): $28.980M — Significant improvement from a $3.437M net loss in YTD 2024
Total Revenue (Q3 2025): $47.956M — Decreased from $51.384M in Q3 2024
Product Revenue (Q3 2025): $46.953M — Decreased from $49.806M in Q3 2024
Gain from Earnout Liabilities (YTD 2025): $11.776M — Swing from a $18.825M loss in YTD 2024
Cash and Cash Equivalents (Sept 30, 2025): $28.048M — Decreased from $39.342M at Dec 31, 2024
Net Cash Used in Financing Activities (YTD 2025): $34.424M — Primarily due to repurchase liabilities and stock repurchases
Class A Common Stock Shares Outstanding (Nov 5, 2025): 32,268,460 — Reflects recent share activity
Filing Date: 20251105 — Date of Report
Total Revenue: $49.7M — Increased 21.8% from $40.8M in Q2 2024 to $49.7M in Q2 2025
Net Income (Loss): -$1.5M — Shifted from a $1.2M net income in Q2 2024 to a $1.5M net loss in Q2 2025
Revenue Growth: 21.8% — Year-over-year increase in total revenue for Q2 2025
SG&A Increase: 25.3% — Percentage increase in selling, general, and administrative expenses to $35.7M in Q2 2025
Acquisition Cost: $10.0M — Amount paid for the acquisition of FH Investments, Inc. on March 18, 2025
Pellet Procedures Revenue: $42.9M — Increased 17.5% for the three months ended June 30, 2025

Forward-Looking Statements

{"claim":"LMR Partners LLP will maintain a significant, but potentially adjusted, stake in biote Corp. throughout 2024.","entity":"LMR Partners LLP","targetDate":"December 31, 2024","confidence":"medium"}

Frequently Asked Questions

What are the latest SEC filings for Biote CORP. (BTMD)?

Biote CORP. has 42 recent SEC filings from Jan 2024 to Apr 2026, including 24 8-K, 6 10-Q, 5 SC 13G/A. Each filing includes an AI-generated plain-English summary.

What is the overall sentiment of BTMD filings?

Across 42 filings, the sentiment breakdown is: 40 neutral, 2 mixed. The dominant sentiment is neutral.

Where can I find Biote CORP. SEC filings explained simply?

ReadTheFiling provides AI-powered plain-English summaries of all Biote CORP. (BTMD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.

What are the key financial highlights for Biote CORP.?

Key financial highlights from Biote CORP.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.

What is the investment thesis for BTMD?

The investment thesis for BTMD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.

Who are the key executives at Biote CORP.?

Key executives identified across Biote CORP.'s filings include Dr. Gary S. Donovitz, Teresa S. Weber, Dr. David G. Astrella, Dr. Jonathan M. Weisberg, Dr. Paul R. Savage and 10 others.

What are the main risk factors for Biote CORP. stock?

Of BTMD's 32 assessed filings, 0 were flagged high-risk, 16 medium-risk, and 16 low-risk.

What are recent predictions and forward guidance from Biote CORP.?

Recent forward-looking statements from Biote CORP. include guidance on {"claim":"LMR Partners LLP will maintain a significant, but potentially adjusted, stake in biote Corp. throughout 2024.".